atrophy

(redirected from Charcot-Marie-Tooth disease)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
Related to Charcot-Marie-Tooth disease: multiple sclerosis, waxy degeneration, Charcot foot, Cat eye syndrome, Transverse myelitis
References in periodicals archive ?
The authors describe a case of Charcot-Marie-Tooth disease (CMT) referred to a lipid clinic for management of combined hyperlipidemia.
Clinically, serial casting is not always well tolerated by individuals with Charcot-Marie-Tooth disease.
Polymorphic short tandem repeats for diagnosis of the Charcot-Marie-Tooth disease 1A duplication.
DNA duplication associated with Charcot-Marie-Tooth disease type 1A.
an initial grant for work on Charcot-Marie-Tooth disease from Oseo, the French state innovation agency (2007).
Charcot-Marie-Tooth disease (CMT, [4] MIM 118220) is a common Mendelian disorder with a frequency of 1 in 2500 (1).
Personal Genome Sequencing Identifies Mutation Linked to Charcot-Marie-Tooth Disease
About Hereditary Neuropathy Foundation Hereditary Neuropathy Foundation (HNF) is a non-profit 501(c)3 organization whose mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth disease (CMT) and related inherited neuropathies, support patients and families with critical information to improve quality of life, and support research that will lead to treatments and cures.
Two examples of diseases caused by alterations in gene dosage are the autosomal dominant demyelinating peripheral neuropathy Charcot-Marie-Tooth disease type 1A (CMT1A) [1] and hereditary neuropathy with liability to pressure palsies (HNPP).
The Agreement Concerns Innovative Drug Candidates Issued from the Pleotherapy[TM] Technology Intended for the Treatment of Charcot-Marie-Tooth Disease
19, 2014 /PRNewswire-USNewswire/ -- An entire month is dedicated to one of the most common forms of inherited neuropathies C Charcot-Marie-Tooth disease (CMT) C a debilitating neuromuscular disease affecting the arms, hands, feet and legs, causing extreme muscle atrophy, weakness, and foot and hand deformities.
Pharnext retains worldwide commercialization rights to PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT 1A).

Full browser ?